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Abstract
Targeting cellular function as a system rather than on the level of the single target significantly increases therapeutic
potency. In the present study, we detect the target pathway of salvianolic acid B (SalB) in vivo. Acute myocardial infarction
(AMI) was induced in rats followed by the treatment with 10 mg/kg SalB. Hemodynamic detection and pathological stain, 2-
dimensional electrophoresis, MALDI-TOF MS/MS, Western blot, pathway identification, apoptosis assay and transmission
electron microscope were used to elucidate the effects and mechanism of SalB on cardioprotection. Higher SalB
concentration was found in ischemic area compared to no-ischemic area of heart, correlating with improved heart function
and histological structure. Thirty-three proteins regulated by SalB in AMI rats were identified by biochemical analysis and
were classified as the components of metabolism and apoptosis networks. SalB protected cardiomyocytes from apoptosis,
inhibited poly (ADP-ribose) polymerase-1 pathway, and improved the integrity of mitochondrial and nucleus of heart tissue
during AMI. Furthermore, the protective effects of SalB against apoptosis were verified in H9c2 cells. Our results provide
evidence that SalB regulates multi-targets involved in the apoptosis pathway during AMI and therefore may be a candidate
for novel therapeutics of heart diseases.
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Introduction
Traditionally, the goal in drug development is to design selective
compounds that act on single disease target to achieve desired
potency with low side effects. This strategy of ‘‘one-gene, one-
drug, one-disease’’ turns out to be unsuccessful for the majority of
‘‘complex disease’’ because pathogenesis of many diseases is multi-
factorial rather than due to a single cause [1]. Cardiovascular
diseases, the leading cause of mortality and morbidity in the world,
are one class of such ‘‘complex diseases’’. Many cardiovascular
diseases are the results of relatively subtle dysfunctions of multi
physiological pathways [2]. Development of new compounds
targeting different pathways and acting as multi-target inhibitors
provides new strategies for cardiovascular therapy. Such poly-
pharmacological approach to target cellular function as a whole
rather than each individual target within the pathway may
increase therapeutic potency [3].
Salvia miltiorrhiza has been widely used in clinic in China for the
treatment of various microcirculatory disturbance-related diseases,
such as cardiovascular disease, cerebrovascular disease, renal
dysfunction, liver fibrosis, and diabetic vascular complication [4].
Salvianolic acid B (SalB) is the major water-soluble component
extracted from Salviae miltiorrhizae. Several lines of in vitro
experiments have demonstrated biological activities of SalB in
promoting cellular proliferation and differentiation, anti-apoptotic,
preserving normal cellular functions [5–9]. Our recent data
showed that SalB protects against cardiac remodeling through
inhibition of matrix metalloproteinase-9 and fibrosis [10]. Base on
these reports, SalB seems to have pleiotropic effects and may act
on multiple molecular targets, making it a suitable candidate for
polypharmacology strategy to develop novel cardiovascular
therapeutics.
In the present study, we used myocardial infarction as a disease
model to evaluate protective effect of SalB on diseased heart. A
series of assays were employed to explore the potential mechanism
of SalB cardioprotection including biochemical, cardiophysiologi-
cal, histopathological, and pathway analysis. Our results indicated
that SalB regulated multi-targets involved in the apoptosis
pathway during acute myocardial infarction and therefore might
be a candidate for further polypharmacology research on novel
therapeutics of cardiovascular diseases.
Materials and Methods
Animal model and SalB treatment
Wistar male rats (230–250 g) were purchased from Shanghai
Center of Experimental Animals, Chinese Academy of Sciences.
The purity of SalB (purchased from Shanghai Yousi Bio-Tech
Co., Ltd.) was more than 99% evaluated by high-performance
liquid chromatography (Figure S1) and the chemical structure of
SalB was elucidated by
1H NMR and
13C NMR (Figure S2, S3,
S4). AMI was introduced by ligation of the left anterior descending
coronary artery near the main pulmonary artery as described
previously [11]. Animals were randomly assigned into four groups:
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given SalB (Sham-SalB, n=40), AMI rats given saline (AMI,
n=30), AMI rats given SalB (AMI-SalB, n=40). Thirty min later
and 24 h later after surgery, saline or SalB was administered
through intravenous (IV) injection (10 mg/kg). The dose of
10 mg/kg was set according the protection of SalB on ischemic
area (Figure S5). Ten out of 40 rats from Sham-SalB or AMI-SalB
were used to measure tissue distribution of SalB. This study was
carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of National
Institutes of Health. All protocol was approved by Institutional
Animal Care and Use Committee at Shanghai Institute of Materia
Medica (IACUC number: SIMM-AE-GDA-2010-03).
Tissue distribution of SalB
Tissue-distribution of SalB in Sham rats or AMI rats was
detected. One-hundred-fifty mg of each tissue sample was
homogenized in methanol for approximately 1 min (1:5 ration
of tissue to methanol) using a Fluko F6/10 superfine homogenizer.
Ultrasonic treatment was applied for 5 min, and then the resulting
samples were centrifuged at 3500 rpm for 5 min at 4uC.
Supernatant was used to detect SalB concentration by chroma-
tography (Agilent Waldbronn, Germany). An API 4000 triple
quadrupole mass spectrometer equipped with a TurboIon Spray
ionization interface (Applied Biosystems, Canada) was used for
mass analysis and detection. Data acquisition was performed with
Analyst 1.4.1 software (Applied Biosystems, USA).
Measurements of hemodynamic parameters and cardiac
output
Twenty-five hours after surgery, the rats were anesthetized, and
a Mikro-tipped SPR-320 catheter (Millar Instruments Inc) was
inserted through the right carotid artery into left ventricle. Heart
rate, mean arterial pressure (MAP), left ventricular systolic
pressure (LVSP), end-diastolic pressure (EDP) of rats were
recorded by PowerLab 8/30 instrument (ADInstruments, Aus-
tralia). Maximal rate of pressure development for contraction
(+dP/dtmax) and maximal rate of pressure development for
relaxation (2dP/dtmax) were all calculated from the continuously
collected pressure signal. For cardiac output detection, rats were
anaesthetized, placed on a heating pad supplied with ventilation.
The thymus lobes were pulled apart to expose the aorta. The
ascending aorta was dissected and a transonic perivascular MA2.5
PSL flow probe (Transonic Systems, USA) was positioned around
the aorta. Appropriate amount of ultrasound transmission gel was
injected into the space between the probe and the aorta. Flow
signals were then acquired by TS420 flowmeter and PowerLab
recording unit.
Histopathological detection
After detection of hemodynamic parameters, the heart samples
were fixed by 4% neutral-buffered paraformaldehyde for 24 h,
and the specimens were paraffin-embedded, cut at 5 mm and were
stained with haematoxylin and eosin. Photomicrographs were
taken using an Olympus BX51 microscope plus Olympus DP71
CCD camera (Olympus Corporation, Japan).
Two-dimensional electrophoresis
Heart tissues from rat infarct area were pulverized under liquid
nitrogen and then detergent soluble proteins were extracted by
incubation in lysis buffer. Homogenization was achieved by
ultrasonication on ice, then centrifugation at 15, 0006g for 30 min
at 4uC. The supernatants were used for two-dimensional
electrophoresis as described previously using Bio-Rad 2-DE
system [12]. Briefly, 150 mg protein sample was applied for IEF
using the ReadyStrip IPG Strips. The strips were placed into a
Protein IEF cell and were rehydrated at 50 V for 12 h and then
the proteins were separated based on their pI. After IEF, the IPG
strips were equilibrated for 15 min in a buffer containing 50 mM
Tris-HCL, pH 8.8, 30% glycerol; 7 M urea, 2% SDS and 1%
DTT, and then applied on to 12% homogeneous SDS-PAGE gels
for electrophoresis using a PROTEIN II xi Cell system (Bio-Rad,
USA). The gels were then silver stained using Bio-Rad Silver Stain
Plus kit according to the manufacturer’s instructions. For each
protein sample, three independent electrophoreses were per-
formed to ensure reproducibility.
Image analysis and MALDI-TOF MS/MS
The silver-stained gels were scanned using a Densitometer GS-
800 (Bio-Rad, USA) and the images were analyzed using PD-
Quest software (Bio-Rad, USA). Proteins of interest were excised
from the gels with EXQuest Spot Cutter (Bio-Rad, USA), and MS
analysis was performed as described previously [13]. Briefly, gel
pieces were destained for 2 min, washed twice with deionized
water and shrunk by dehydration in ACN. The samples were then
swollen in a digestion buffer containing 25 mM ammonium
bicarbonate and 12.5 ng/ml trypsin at 4uC. After a 30 min
incubation, the gels were digested for over 12 h at 37uC. Peptides
were extracted twice using 0.1% TFA in 50% ACN, and the
extracts were dried under N2. For MALDI-TOF MS/MS,
peptides were mixed with 0.7 ml MALDI matrix and spotted on
the 192-well stainless steel MALDI target plates. MS measure-
ments were carried out on an ABI 4700 Proteomics Analyzer with
delayed ion extraction (Applied Biosystems). Data search files were
generated and then the database search was performed by using
the MASCOT search engine (Matrix Science, United Kingdom).
Protein homology identifications of the top hit (first rank) with a
relative score exceeding 95% probability and additional hits
(second rank or more) with a relative score exceeding 98%
probability threshold were retained. Proteins with protein score
more than 62 and best ion score more than 30 were accepted.
Pathway identification
KEGG was used to analysis all differential expressed proteins in
2-DE experiment and a list of target pathways was generated [14].
Figure 1. Accumulation of SalB in ischemic area of heart. All the
values are expressed as mean 6 S.E. ***p,0.001 versus no-infarct area
of Sham. n=10 for every group.
doi:10.1371/journal.pone.0024036.g001
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pathways, linked pathways with these target pathways were also
retrieved from KEGG database and the pathway networks were
constructed using Pajek network visualization software (version
1.25).
Western blot analysis
Western blot analysis was performed on the infarct samples
using antibodies against the following proteins purchased from
Cell Signaling: poly(ADP-ribose) polymerase-1 (PARP-1), cleaved
PARP-1, IKKa, IKKb, p-IKKa, NF-kB, GAPDH. Antibody for
L-lactate dehydrogenase B (LDHB) was purchased from Abcam
and b-actin was from Beyotime. The aliquots of 25 mg protein
were electrophoresed on a SDS–PAGE gel and transferred to
polyvinylidene difluoride membrane. The membrane was blocked
for 1 h in blocking buffer containing 5% non-fat dry milk and
0.07% Tween 20 in Tris-buffered saline (TBS-T), followed by
incubation with indicated antibodies in blocking buffer overnight
at 4uC. Then, the membrane was washed three times with TBS-T
for 30 min and incubated at room temperature for 1 h with
secondary antibody. Detection was done using the ECL Western
Blotting Detection System (Pierce, USA). The bands density for
corresponding protein was quantified using a MiniBis system
(DNR Bio-Imaging Systems Ltd, Israel).
TUNEL assays
To evaluate apoptosis in infarct area of rat heart, terminal
deoxynucleotide transferase-mediated dUTP nick-end labeling
(TUNEL) assay using FragEL
TM DNA Fragmentation Detection
Kit was carried out according to the manufacturer’s instructions
(Calbiochem, USA). Briefly, the heart samples were fixed by
incubating in 4% neutral-buffered paraformaldehyde for 24 h,
Figure 2. SalB improves cardiac function of AMI rats. Mean arterial pressure (MAP), maximum rate of pressure development for relaxation
(2dP/dtmax), left ventricular systolic pressure (LVSP), maximum rate of pressure development for contraction (+dP/dtmax), end-diastolic pressure
(EDP), and cardiac output were demonstrated. All the values are expressed as mean 6 S.E. *p,0.05, ***p,0.001 versus Sham; #p,0.05, ##p,0.01
versus AMI. n=30 for every group.
doi:10.1371/journal.pone.0024036.g002
SalB Performs Cardioprotection against Apoptosis
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24036and the specimens were then paraffin-embedded, cut to 5 mm
slices. The sections were de-paraffinized, rehydrated, and
permeabilized by incubation in solutions containing proteinase
K. After equilibration and labeling reaction, the results were
evaluated using BX51 fluorescence microscope plus Olympus
DP71 CCD camera (Olympus Corporation, Japan). Total cells
were visualized at 330–380 nm for DAPI staining, and apoptotic
cells were visualized at 465–495 nm for FITC staining.
Transmission electron microscopy
Hearts were dissected and small pieces from ischemic area were
cut and fixed with 2.5% glutaraldehyde in 0.1 M cacodylate buffer
for 2 h, post-fixed in 1% osmium tetroxide in 0.1 M cacodylate
buffer for 1 h and embedded as monolayers in LX-112 (Ladd
Research Industries, USA). Ultrathin sections were cut and
contrasted with uranyl acetate followed by lead citrate and
observed with a Tecnai 12 BioTwin transmission electron
microscope (Philips Electronic Instruments, USA). Random
sections were selected for analysis by an electron microscopy
technician blinded to the treatments.
Cell culture and hypoxia challenge
Rat H9c2 cells (Cell bank of Chinese Academy of Sciences,
Shanghai) were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal calf serum and
cultured in 5% CO2 at 37uC. All media and culture reagents were
products of Gibco (Grand Island, NY) unless specified otherwise.
Just before induction of hypoxia challenge, vehicle or SalB was
added into the serum free culture media and the cells were placed
into a humidified hypoxia incubator (Tri-Gas Incubator, Heal
Force) to achieve a low-oxygen environment (95% N2 and 5%
CO2) for 24 h. Mitochondrial membrane potential detection and
DAPI stain were performed following.
Mitochondrial membrane potential detection using JC-1
A fluorescent cationic dye, 5,59, 6,69-tetrachloro-1,19, 3,39-
tetraethylbenzimidazolyl-carbocyanine iodide, commonly known
as JC-1 (Beyotime), was used to measure mitochondrial membrane
potential. After hypoxia treatment, cells grown on cover slips were
washed twice with PBS and incubated with 5 mg/ml JC-1 dye in
serum-free medium for 20 min at 37uC. Cells were washed three
times with PBS and analyzed immediately under a fluorescent
microscope after mounting with DAKO mounting medium. JC-1
fluorescence was measured from single excitation (488 nm) with
dual emission (shift from green 530 nm to red 590 nm). Green
fluorescence reveals the monomeric form of the JC-1 molecule,
which appears in the cytosol after mitochondrial membrane
depolarization. Red fluorescence is emitted from the aggregation
of JC-1 molecules, which is formed in the inner membrane of
actively respiring mitochondria. Photomicrographs were taken
using an Olympus BX51 microscope plus Olympus DP71 CCD
camera (Olympus Corporation, Japan).
Apoptosis detection by staining of nuclei with DAPI
The nuclei of H9c2 cells were stained with chromatin dye DAPI
(Invitrogen, USA). Briefly, after treatment, the cells were fixed
with 4% paraformaldehyde for 20 min, washed twice with PBS,
and incubated with 10 mg/ml DAPI in PBS at room temperature
for 30 min. After three washes, the cells were observed under an
Olympus fluorescence microscope (BX51) plus Olympus DP71
CCD camera. Total cells and apoptosis cells per field were
counted by a blinded investigator. The quantitative data was
expressed as percentage of apoptosis cell per field.
Statistical analysis
All quantitative data are reported as mean 6 S.E. Statistical
analyses were performed using one-way ANOVA to compare
means, followed by post hoc test. p,0.05 was considered to be
statistically significant.
Results
Accumulation of SalB in the ischemic area of heart
First we analyzed SalB concentration in several major organs.
1 h after intravenous administration of 10 mg/kg SalB, major
Figure 3. SalB improves heart structure of AMI rat detected by H&E stain. Representative photomicrographs from heart tissue of Sham,
Sham-SalB, AMI, AMI-SalB groups were shown. (A) 1006magnification. (B) 4006magnification. n=10 for each group.
doi:10.1371/journal.pone.0024036.g003
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homogenate was prepared. The concentration of SalB in heart is
60.866.7 ng/g (no-infarct area of Sham); 79.2612.8 (no-infarct
area of AMI); 65.169.2 ng/g (infarct area of Sham) and
928.26135.8 ng/g (infarct area of AMI), respectively. There was
no difference of SalB concentration in liver and kidney between
Sham and AMI rats, the concentrations were all below 50 ng/g
(Figure 1). The higher concentration of SalB at ischemic area of
heart promoted us to concentrate this area for further mechanism
research.
SalB improves left ventricle function of AMI rat
To evaluate the possible protective effect of higher concentration of
SalB in heart of AMI rats, we measured several major haemodynamic
parameters for left ventricle contractility, including MAP, 2dp/dtmax,
LVSP, +dp/dtmax, and EDP along with cardiac output (Figure 2).
Compared to rats in the Sham group, left ventricle dysfunction in
AMI rats was observed with significant decrease of 2dp/dtmax
(25153.26257.4 mmHgS
21versus 29578.06546.0 mmHgS
21,p,
0.001), LVSP (96.762.5 mm Hg versus 121.461.8 mm Hg,
p,0.001), +dp/dtmax (6134.16441.6 mmHgS
21 versus 9184.66
Table 1. Statistical analysis of 2-DE purified proteins changing in abundance following 24 h MI.
Spot no. PPM
Sham Sham-SalB AMI AMI-SalB
1 0.03160.060 0.04760.080 77.44620.41** 43.53631.79#
2 0.03160.060 0.04760.080 129.23651.58** 64.88637.44#
3 65.95634.70 108.58657.93 178.07664.22** 375.036222.66#
4 0.01760.039 1.6264.28 21.97630.42* 0.0460.052#
5 60.05619.96 81.72661.24 95.14620.92** 59.20629.08##
6 10195.0764565.27 11004.5164404.93 4084.7162940.35** 1999.196585.55#
7 0.03160.060 297.376220.76** 552.396297.49** 242.35677.83#
8 5123.7962121.37 5493.8662338.04 3523.4961814.43* 1925.076575.30##
9 608.766815.45 1061.7161353.48 2982.8662114.23** 962.096595.63#
10 1511.336607.93 792.08679.81** 687.976409.98** 414.326170.65#
11 106.34676.43 154.806107.02 210.646121.70* 103.03633.22#
12 0.01560.04 0.04060.08 54.89629.99** 0.05460.07##
13 129.39654.38 135.09686.40 68.23628.87** 37.35631.95#
14 781.386250.70 561.726180.01** 292.166170.23** 139.26641.86##
15 42.92634.02 33.32623.70 0.09360.08** 17.19610.94**
16 53.20629.99 48.99629.58 104.55647.66** 64.22630.20#
17 241.556115.54 269.826123.72 446.346199.24** 323.656130.49
18 391.196237.48 346.716211.54 1057.866403.52** 1451.146435.50#
19 1687.696845.21 1428.556845.21 310.116149.48** 189.72667.31#
20 73.58636.75 24.07665.91* 159.28675.45** 247.92694.95#
21 83.01667.88 118.02690.42 296.846244.00** 166.416158.52
22 245.956110.24 180.276104.29 98.27644.93** 50.50616.83##
23 113.45671.38 113.25671.12 499.886221.35** 834.656241.87##
24 152.40677.40 73.01683.24** 87.38650.26* 37.85623.21##
25 407.246257.81 447.066306.43 210.85666.85** 129.36665.89##
26 1443.746522.57 1175.326553.83 311.306141.47** 173.95659.41##
27 60.58656.25 61.02653.62 105.84655.73* 39.78621.18##
28 218.34696.84 162.44679.81 139.34652.49* 98.96625.96#
29 186.22673.60 147.78665.38 84.43626.32** 54.68634.47#
30 1407.176653.52 1545.666773.55 393.716255.81** 222.77698.22#
31 77.76645.55 68.01639.41 33.33617.79** 15.12610.97##
32 341.836200.10 260.626129.44 77.42671.56** 23.63622.87#
33 303.746182.15 555.256633.07 172.836104.76* 63.01635.91##
*p,0.05,
**p,0.01,
***p,0.001 versus Sham;
#p,0.05,
##p,0.01,
###p,0.001 versus AMI.
doi:10.1371/journal.pone.0024036.t001
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e24036Figure 4. Differentially expressed proteins resolved by 2-DE analysis, identified by MS and Western blot. (A) Representative 2-DE gel
images from Sham, Sham-SalB, AMI and AMI-SalB. Differentially expressed spots chosen for further MALDI-TOF MS/MS analysis were indicated by
arrows. n=6 for every group. (B) Close-up image of protein spot 4 on different treatments. (C) MALDI-TOF MS/MS spectra of the spot 4 cut from the
2-DE gel resulted in the identification of LDHB. (D) MS/MS profile of the peptide with a mass of 957.6 Da from spot 4. (E) Western blot of LDHB in
different treatments, one lane represents one rat. n=10 for every group. (F) Quantitative data of LDHB for Western blot. *p,0.05 versus Sham;
###p,0.01 versus AMI. n=10 for each group. At least three time experiments were repeated and the representative figures were shown.
doi:10.1371/journal.pone.0024036.g004
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21, p,0.001), and increase of EDP (10.862.1 mmHg
versus 3.761.8 mmHg, p,0.05). SalB treatment reduced the degree
of impairment of left ventricle function with the elevation of values
of 2dp/dtmax (26260.26233.3 mmHgS
21 versus 25153.26
257.4 mmHgS
21, p,0.01), +dp/dtmax (7603.26348.1 mmHgS
21
versus 6134.16441.6 mmHgS
21, p,0.05), compared with the
AMI group. No detectable difference in MAP was observed among
all groups. No significant difference in hemodynamic parameters
was found between the Sham-SalB group and the Sham group. To
further evaluate cardiac function of rats from different treatment
groups, transonic flowmeter was used to measure the cardiac
output. The value of cardiac output for AMI rats decreased to
35.961.0 ml/min from 57.261.9 ml/min observed in rats from
the Sham group (p,0.001). With the SalB treatment, the cardiac
output in these rats improved to 41.661.0 ml/min (p,0.01).
SalB improves left ventricle structure of AMI rat
To explore the structural basis leading to observed impairment
of left ventricle function, histopathological evaluation of heart
samples from all groups was performed. The cell alignment was
regular and no obvious damage was detected in the myocardium
of Sham rats and Sham-SalB rats. However, marked cellular
degeneration, interstitial edema and coagulation necrosis in the
ischemic region were observed in AMI rats. Upon SalB
treatment, there was a profound increase of cross striation and
cell integrity in samples from AMI-SalB rats, suggesting that SalB
Table 2. Identification of proteins significantly altered in ischemic area of heart after 24 h MI.
Spot No. Identification
Accession
No. of NCBI
database
Theoretical
MW (Da)
Theoretical
pI
protein
score
1 vinculin (predicted), isoform CRA_a 149031250 123555.8 5.54 99
2 actinin alpha 2 157951643 103768.3 5.31 104
3 mitochondrial ribosomal protein L45 157786676 35417.4 9.44 64
4 L-lactate dehydrogenase B 6981146 36589.1 5.7 112
5 TNF receptor-associated protein 1 precursor 84781723 80410.8 6.56 219
6 fatty acid binding protein 3, muscle and heart 13162363 14765.6 5.9 414
7 mitochondrial aldehyde dehydrogenase precursor 45737868 55565.2 7.63 246
8 Malate dehydrogenase 1, NAD (soluble) 37590235 36461 5.93 116
9 Serum albumin 124028612 68686.1 6.09 297
10 enolase 1, (alpha) isoform 1 56107 47086.2 6.16 150
11 similar to T-complex protein 1 subunit alpha (TCP-1-alpha) (CCT-alpha) 109472340 51646.1 7.98 239
12 enolase 1, (alpha) isoform 1 158186649 47098.2 6.16 301
13 glycerol-3-phosphate dehydrogenase 1 (soluble) 57527919 37428.2 6.16 112
14 peroxiredoxin 6 16758348 24803 5.64 343
15 NADH dehydrogenase (ubiquinone) Fe-S protein 3 157817227 30207.6 7.07 134
16 rCG51928, isoform CRA_b 149030414 27055.4 5.37 104
17 protein disulfide isomerase associated 3, isoform CRA_a 149023097 53553 7.1 356
18 vitamin D-binding protein precursor 51260133 53483 5.65 145
19 creatine kinase, brain, isoform CRA_a 149044074 35862.1 6.27 274
20 Death associated protein 3 55249775 44466 9.08 60
21 calreticulin, isoform CRA_b 149037838 24484.2 5.38 92
22 Temporarily Assigned Gene name family member (tag-58) 109492050 574015.9 5.11 70
23 Ba1-647 33086640 42447.5 6.11 85
24 pyrophosphatase (mapped), isoform CRA_b 149038730 34007 5.21 91
25 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma
polypeptide
9507245 28284.9 4.8 154
26 aldo-keto reductase family 1, member B1 6978491 35774.3 6.26 203
27 rCG23609, isoform CRA_b (Myosin) 149063939 216384.4 5.68 65
28 adenine phosphoribosyltransferase 61556832 19533.4 6.17 246
29 glyoxalase 1 46485429 20806.3 5.12 121
30 Chain A, Rat Phosphatidylethanolamine-Binding Protein 158428857 21060.5 5.47 207
31 RAN binding protein 2 109509431 344179.5 5.73 65
32 fatty acid binding protein 3, muscle and heart 13162363 14765.6 5.9 303
33 Desmin 38197676 53390.1 5.21 539
doi:10.1371/journal.pone.0024036.t002
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(Figure 3).
Differential protein expression profile among different
groups
Left ventricular myocardial samples taken from ischemic area
were subjected to three independent 2-DE analyses under the same
conditions to assure reproducibility. More than 560 protein spots
were detected in samples of each rats from each treatment group
(n=5). Between samples from Sham and AMI rats, thirty-three
protein spots exhibited significantly difference in intensity (p,0.05).
Among those, sixteen of the thirty-three spots were considerably up-
regulated while other seventeen spots were significantly down-
regulated in samples from AMI rats compared to those from Sham
rats (Table 1). These spots were labeled and further analyzed using
MALDI-TOF MS/MS (Figure 4A; Table 2). The close-up image
for spot 4 was shown and the protein species for this spot was
identified as LDHB in the experiment described below (Figure 4B).
During MI, damaged myocardial cells release LDHB into the
bloodstream and causes LDHB level to increase. LDHB has
fundamental importance in the regulation of heart metabolism and
further involves in the regulation of heart function [15]. Since
LDHB is generally used as an index for myocardial infarction, we
chose LDHB as the candidate protein to verify the data of 2-DE
gels. The representative MALDI-TOF MS/MS spectrum for
LDHB protein retrieved from the 2-DE gel (Figure 4C) and the
detail MS/MS profile of the peptide with a molecular mass of
957.6 Da (Figure 4D) were shown. In addition, Western blot
analysis was also used to confirm 2-DE results, complementary to
MALDI-TOF MS/MS. Representative blots (Figure 4E) and
quantitative result (Figure 4F) of Western blot analysis on LDHB
protein were shown. Overall, 1.9160.58 fold increase in LDHB
expression was found in AMI rats compared with Sham rats
(p,0.05), and SalB treatment reduced the level ofLDHBexpression
compared with AMI (p,0.001), suggesting the same expression
pattern of LDHB detected by Western blot and 2-DE gel (Table 1).
SalB protects AMI heart through regulation on
metabolism and apoptosis pathways
Based on protein expression profile illustrated in 2-DE analysis,
we deduced target pathways based on proteins listed in Table 1
and constructed two main pathway networks related to metabo-
lism and apoptosis according KEGG and Pajek analysis. In which
the conjunctive pathways were constructed to link the target
pathways. The metabolism network (Figure 5A) included 23 target
pathways marked by red rectangle and other conjunctive pathways
marked by grey ellipse; while the apoptosis network (Figure 5B)
included 11 target pathways marked by red rectangle and other
conjunctive pathways marked by grey ellipse. The detail
information of each pathway was listed underneath, metabolism
related pathways in red and apoptosis related in blue. It is very
prominent that 3 target pathways (number 46, number 50,
number 63) were found to directly connect with apoptosis pathway
(number 51; green ellipse), suggesting that anti-apoptosis mecha-
nism may play a key role in SalB cardioprotection.
SalB protects cardiomyocytes from apoptosis
To further investigate the potential anti-apoptosis mechanism
for cardio-protection of SalB, we employed in situ TUNEL assay to
examine apoptosis cardiomyocytes from different treatment
groups (Figure 6A). Higher percentages of apoptotic cells were
found in AMI rats (69.063.3%) compared with Sham rats
(8.961.5%) (p,0.001). SalB treatment reduced the percentage
of apoptotic cells to 48.763.2%, (p,0.001) comparing to AMI
(Figure 6B). These data provided the direct evidence that cardio
protection of SalB was related to its inhibition on apoptosis.
Regulation of SalB on apoptosis proteins in ischemic area
of heart
We further examine the effects of SalB on PARP-1 and NF-kB,
two pivotal signal pathways for apoptosis. Protein samples from
infarct area of heart were subjected to SDS-PAGE and Western
blot analysis. For proteins in the PARP-1 signal pathways,
significant elevation in expression level of PARP-1 (p,0.05) and
cleaved-PARP-1 (p,0.001) was found in samples from AMI rats
compared to that from Sham rats; SalB treatment led to a
significant decrease in expression level of PARP-1 (p,0.05) and
cleaved-PARP-1 (p,0.001) compared to the AMI group
(Figure 7A and 7B). For NF-kB signal pathway, significant
elevation in levels of p-IKKa (p,0.05) and nuclear NF-kB
(p,0.05) was found in samples from AMI rats compared to that
from Sham rats, while no significant change was found between
the AMI and AMI-SalB groups (Figure 7A and 7B). For IKKa,
IKKb and plasma NF-kB, no significant difference was found
between different treatment groups.
SalB protects the integrity of mitochondria, nucleus and
intercalated disk of heart tissue
Because mitochondria and nucleus are two main intracellular
organelles related to apoptosis, it becomes interesting to us to
explore the potential protective effect of SalB on the integrity of
mitochondria and nucleus during AMI. The structures of
mitochondria and nucleus were examined using transmission
electron microscopy. The sarcomeres and mitochondria were in
regular orientation and homogenous length in Sham and Sham-
SalB rats. However in AMI rats, mitochondrial matrix of
cardiomyocytes showed severe damage. The mitochondrial cristae
showed partial disruption with otherwise normal morphology in
AMI-SalB rats (Figure 8A). Nuclei structure appeared to be
normal in Sham and Sham-SalB rats with a normal nuclear size,
but nuclei from AMI rats displayed an irregular, folded nuclear
envelope. An improved nuclei morphology and homogenous
nuclei matrix were observed in AMI-SalB rats (Figure 8B).
Intercalated disks are highly organized cell-cell structures, which
connect cardiomyocyte to one another. A long and integral
intercalated disk with many microprojections was observed in
Sham and Sham-SalB rats. A convoluted and dissociated
intercalated disk with few microprojections was observed in AMI
rats, while, SalB treatment improved the structure of intercalated
disk (Figure 8C).
SalB protects mitochondria function and against
apoptosis in H9c2 cells
To further confirm the protection of SalB on cardiac cells, H9c2
cells were used. The change in mitochondrial membrane potential
was measured using JC-1 that exists as aggregates in mitochondria
with normal potential resulting in red fluorescence or as cytoplasmic
monomers at low mitochondrial potentials resulting in green
Figure 5. Bioinformatic analysis of proteins identified on 2-DE from the hearts of rats with different treatment. (A) Metabolism
pathway network was constructed with 23 target pathways. (B) Apoptosis pathway network was constructed with 11 target pathways. Red rectangles
represent target pathways; grey ellipses represent conjunctive pathways. The apoptosis pathway (number 51) was emphasized in green ellipse.
doi:10.1371/journal.pone.0024036.g005
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PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24036Figure 6. SalB protected cardiomyocytes from apoptosis detected by TUNEL assay in ischemic area of heart. (A) Representative
pictures of each treatments. The total cells were identified by DAPI stain, and the positive apoptosis cells were identified by FITC stain. (B)
Quantitative data of apoptosis cells. ***p,0.001 compared with Sham, ###p,0.001 compared with AMI. n=10 for each group. At least three time
experiments were repeated and the representative figures were shown.
doi:10.1371/journal.pone.0024036.g006
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beginning of the death signaling pathway. Normoxic control cells
exhibited numerous brightly stained mitochondria that emitted red/
orange fluorescence. With hypoxia treatment, clear formation of
monomeric JC-1 was observed, which is indicative of loss of
membrane potential. SalB treatment attenuated this hypoxia induced
formation of JC-1 monomers (Figure 9A), suggesting the protective
effects of SalB on mitochondrial function. DAPI staining was further
used to detect the influence of hypoxia on the nuclear changes of
H9c2 cells. As shown in Figure 9B, nuclei were in the normal
phenotype demonstrating bright and homogenous fluorescence at
normoxic culture condition. The nuclei fluorescence of apoptosis cell
became bright, fragmented and condensed. The quantitative data
indicated that the apoptotic nuclei were increased after 24 h hypoxia
treatment, while this process was inhibited by SalB (Fig. 9C).
Discussion
There have been a number of reports from in vitro studies
illustrating benefit of SalB treatment in different disease and
evidence points to the possibility that SalB may act on multiple
targets leading to a concerted positive effect. However, the
particular pathway and underlying mechanism has yet to be
elucidated. In this study, we attempted to identify potential target
pathways of SalB in cardioprotection in vivo.
Using the AMI rat model we employed the study and observed
a significant improvement, upon SalB treatment, in histopathol-
ogy, cellular morphology, as well as cardio function of disease
heart in AMI rats, along with higher concentration of SalB in
heart tissues. As alternation in histology and function of AMI heart
can be expected to be accompanied with considerable change in
protein expression profile, we then set to conduct proteomics
analysis on samples from infarct area of heart. Thirty-three protein
species (out of a total of over 560 protein species on 2-DE gels) met
the criteria of 1) have a significantly different expression level
between Sham and AMI rats, and 2) have a significantly different
expression level between AMI and AMI-SalB rats. After
characterizing each of these protein species, we constructed two
main pathway networks using KEGG and Pajek analysis tools.
The 33 proteins identified were found to be largely involved in
energy metabolism and apoptosis, suggesting that disturbance of
these two pathways may be representative during AMI, as well as
SalB treatment. Further analysis on pathway networks revealed
that three target pathways were directly linked to apoptosis,
suggesting that apoptosis may be the major pathway for
cardioprotection of SalB.
We then focused on SalB effect on two main apoptosis
pathways. In AMI rats, proteins including KKa,K K b, NF-kB,
p-IKKa in the NF-kB pathway were not significantly affected by
SalB. Between AMI and AMI-SalB rats, however, there were
significant differences in expression levels of PARP-1 and clearved-
PARP-1 proteins in the PARP-1 pathway, implying the involve-
ment of PARP-1 signal in SalB cardio-protection. PARP-1 is an
abundant nuclear protein best known to facilitate DNA base
excision repair [16]. Under pathophysiological conditions, over-
activation of PARP-1 results in unregulated poly (ADPribose)
synthesis and widespread cell death [17]. In addition, increased
activation of PARP-1 has been implicated in the pathogenesis of
acute and chronic myocardial dysfunction [18]. PARP-1 inhibitor
has been demonstrated to more effectively decrease the myocar-
dial remodeling than enalapril treatment [19]. Our findings from
this study were consistent with previous reports that higher PARP-
1 expression level correlated with disease progression while the
decrease in PARP-1 expression in SalB treated AMI rats was
evident along with cardio-protection. The specific target, and in-
depth mechanism of SalB down-regulation on PARP-1 need to be
further explored.
The tissue distribution of SalB was investigated for the first time
in animal with myocardial infarction. Normal rats have been used
to detect SalB tissue distribution after oral administration of SalB
(300 mg/kg), and no detectable SalB was found in heart [20]. The
permeability of SalB is limited in intestinal so its oral bioavail-
ability is only 3.90% in rats [21]. Therefore, SalB concentrations
in blood were similar by oral administration (300 mg/kg) [20] and
intravenous injection (10 mg/kg) in our present study. In the
present study, we compared the distribution of SalB in heart
between normal rats and AMI rat and found very high
accumulation of SalB in ischemic area compared with the other
area of heart. Myocardial ischemia can cause a lot of
pathophysiological changes, such as the enhanced permeability
Figure 7. Regulation of SalB on the protein expression of
PARP-1 an NF-kB signal pathway. (A) Representative micrograph of
Western blot for PARP-1, cleaved-PARP-1, IKKa, IKKb, p-IKKa, plasma NF-
kB, nuclear NF-kB. (B) Quantitative data of Western blot for relative
proteins. *p,0.05, ***p,0.001 compared with Sham, #p,0.05
compared with AMI. n=10 for each group. At least three time
experiments were repeated and the representative figures were shown.
doi:10.1371/journal.pone.0024036.g007
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zone. It is known that the stability of SalB increases with pH value
decrease. It is likely that changed cell membrane permeability
enables SalB penetrate into the ischemic area and decreased pH
value enable SalB stay at ischemic area. Even though we did not
explore the mechanism why so difference on SalB tissue
distribution between normal rat and AMI rat at present stage, it
is also an interesting question for further research.
Data from our previous studies demonstrate that SalB improves
heart contractility and decreases heart fibrosis in rats with heart
failure [10]. Since heart failure is the end stage of heart disease, it
is of great importance to known the effects and mechanism of SalB
on cardio-protection at earlier stages of heart diseases. The present
study is the first to use proteomics technology to conduct
mechanistic research on cardioprotection of SalB in animal
model. We provided direct evidence supporting our conclusion
that the protective effects of SalB are related with its inhibition on
apoptosis. Taken together, our results suggest that SalB is a
promising lead compound for polypharmacology research on
cardiovascular therapy.
Figure 8. SalB improved ultra-structure of ischemic area of heart. (A) Electron micrograph of sarcomere and mitochondria. (B) Electron
micrograph of nuclei. (C) Electron micrograph of intercalated disks marked by asterisk. n=6 for each group. The representative figures were shown.
doi:10.1371/journal.pone.0024036.g008
Figure 9. SalB treatment protected mitochondria function and against apoptosis. (A) Detection of mitochondria membrane potential
using JC-1. (B) Detection of apoptosis using DAPI. (C) Quantitative data of apoptosis cells. **p,0.01 compared with Control, ##p,0.01 compared
with Hypoxia. At least three time experiments were repeated and the representative figures were shown.
doi:10.1371/journal.pone.0024036.g009
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Figure S1 The representative chromatogram of high-
performance liquid chromatography for SalB.
(TIF)
Figure S2
1H NMR spectrum of SalB.
(TIF)
Figure S3
13C NMR spectrum of SalB.
(TIF)
Figure S4 Structure elucidation of SalB. (A) Chemical
structure of SalB. (B)
1H NMR (400 MHz) and
13C NMR
(100 MHz) spectral data for SalB.
(TIF)
Figure S5 SalB decreased infarct sizes dose dependently.
(A) Representative photographs of triphenyltetrazolium chloride
stained rat heart after AMI injury. (B) Graphic representation of left
ventricle infarct size expressed as percentage of total ischemic area
in each group (n=10). # p,0.05 vs. AMI rats, *** p,0.001 vs.
Sham rats.
(TIF)
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